Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Titel:
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Auteur:
Long, Georgina V Stroyakovskiy, Daniil Gogas, Helen Levchenko, Evgeny de Braud, Filippo Larkin, James Garbe, Claus Jouary, Thomas Hauschild, Axel Grob, Jean-Jacques Chiarion-Sileni, Vanna Lebbe, Celeste MandalĂ , Mario Millward, Michael Arance, Ana Bondarenko, Igor Haanen, John B A G Hansson, Johan Utikal, Jochen Ferraresi, Virginia Kovalenko, Nadezhda Mohr, Peter Probachai, Volodymr Schadendorf, Dirk Nathan, Paul Robert, Caroline Ribas, Antoni DeMarini, Douglas J Irani, Jhangir G Swann, Suzanne Legos, Jeffrey J Jin, Fan Mookerjee, Bijoyesh Flaherty, Keith